Key Highlights

 

• Early First-in-Human clinical results have drawn the attention of industry leaders and several of the largest vision care technology companies in the world. 

• Ocumetics will leverage the conference to further engage with global strategic partners to accelerate development and commercialization efforts. 

Calgary, Canada – TheNewswire - April 1, 2026 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSV:V OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in next generation ophthalmic technology, announced today that its leadership team will meet in Washington, D.C. with several potential ophthalmic strategic partners and leading industry stakeholders during the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. The team will provide updates on the Company’s First-in-Human (FIH) clinical program and outline the next phase of its clinical development strategy.

During these meetings, Ocumetics will present the latest results from its ongoing FIH clinical study evaluating the Company’s accommodating intraocular lens technology (the “Ocumetics Lens”). The discussions will focus on early surgical outcomes, patient response, key learnings that are informing the Company’s pathway toward expanding the study, and recent Ocumetics Lens design advancements.

The Company will also provide an update on its planned Group 2 surgeries, which represent the next stage of patient enrollment in its FIH clinical study. The Group 2 procedures are expected to further evaluate the performance and consistency of the Ocumetics Lens while providing additional clinical data to support the Company’s broader regulatory and commercialization strategy.

“Ocumetics is known for pushing the boundaries of ophthalmic innovation,” said Dean Burns, President and CEO of Ocumetics. “Group 1 surgeries provided valuable insights into both surgical performance and patient outcomes of the Ocumetics Lens. Our meetings at ASCRS will allow us to share these learnings directly with potential strategic partners as we prepare for the next phase of the clinical program, including Group 2 surgeries.”

The ASCRS annual meeting is one of the world’s leading gatherings of ophthalmic surgeons, researchers, and medical technology companies. The conference provides a key forum for presenting new technologies and discussing advancements in cataract and refractive surgery. Click here to learn more - https://annualmeeting.ascrs.org.

Ocumetics believes that continued collaboration with surgeons, researchers, and industry partners will be critical as the company advances the Ocumetics Lens technology through clinical development and toward global commercialization.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

 

Ocumetics is in the first-in-human early feasibility study phase of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses, and without perceptible time lag.  

 

FOR FURTHER INFORMATION, PLEASE CONTACT:

 

Dave Burwell

Director, Investor Relations        

dave.burwell@ocumetics.com

 (403) 410-7907       

                       

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Company mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.